Clinical Pharmacy Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
ISPOR Egypt's Chapter, Cairo, Egypt.
Clin Drug Investig. 2019 Feb;39(2):157-168. doi: 10.1007/s40261-018-0730-5.
Egypt faces many challenges when matching patient needs with available resources. Consequently, there has been an increasing interest in pharmacoeconomics as an aid tool in health decision-making to better allocate resources.
To review and evaluate the volume and the quality of published pharmacoeconomic studies in Egypt.
A literature search was conducted in August 2018 using PubMed, Google Scholar, and Cochrane library to identify published Egyptian pharmacoeconomic studies. Articles were included if they were original economic studies, written and published in English, and conducted in Egypt. Each article was assessed independently by two reviewers using the 100-point Quality of Health Evaluation Studies (QHES) scale.
Fifteen studies published between 2002 and 2017 were included in the review. Most of them were cost-effectiveness analyses (60%). The minority used secondary data (33.3%) or adopted modeling techniques (40%). The mean QHES score of the included studies was 70.1 ± 21.8, and approximately 40% of them had a QHES score of more than 80.
Pharmacoeconomic evaluations in Egypt are still in their infancy. The Egyptian guidelines for economic evaluation should be adopted and the EQ-5D-5L value sets should be developed to increase the quality of economic research.
埃及在将患者需求与现有资源相匹配方面面临诸多挑战。因此，人们越来越关注药物经济学作为卫生决策的辅助工具，以更好地分配资源。
综述和评估埃及已发表的药物经济学研究的数量和质量。
于 2018 年 8 月使用 PubMed、Google Scholar 和 Cochrane library 进行文献检索，以确定已发表的埃及药物经济学研究。如果是原始经济学研究，用英文书写和发表，并在埃及进行，则将文章纳入。每篇文章均由两位评审员使用健康评估研究质量 100 分（QHES）量表独立评估。
共纳入了 2002 年至 2017 年发表的 15 项研究。其中大多数为成本效益分析（60%）。少数使用二次数据（33.3%）或采用建模技术（40%）。纳入研究的平均 QHES 得分为 70.1±21.8，约 40%的研究得分为 80 分以上。
埃及的药物经济学评价仍处于起步阶段。应采用埃及药物经济学评价指南，并制定 EQ-5D-5L 值集，以提高经济研究质量。
